Vaccination is proven to be an effective tool in fighting many pathogens. Driven by the market need in the development of therapecutic vaccines, adjuvants are a necessary component of modern vaccines because they can enhance the ability of vaccines to elicit strong, durable, and specific immune responses. But very few adjuvants can efficiently enhance the T-cell responses of vaccines, this has caused vaccines to fail in the past. Our team named “ImmunAdd Therapeutics”, a group of researchers from Spark Taiwan invented a new series of saponin analogs and demonstrated their abilities to enhance vaccine efficacy through increasing antigen-specific CD8+ T-cell mediated immunity. The induction of memory CD8+ T-cell has seen in their combination with anti-cancer vaccines, anti-influenza vaccines, anti-SARS-CoV-2 vaccines.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Oncology
Lead Product in Development:
IA-05
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
